1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Single Dose Promising In Phase I Study

 
• By Andrew McConaghie

Johnson & Johnson has released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.

Johnson_and_Johnson
J&J is planning to include 60,000 volunteers in its Phase III trial, more than any of the other frontrunners.

As Johnson & Johnson begins Phase III trials of its COVID-19 vaccine candidate, it has also just released early data suggesting it is effective in generating an immune response in adults of aged 18-65 and over, with no worrying safety problems detected so far.

J&J’s candidate, JNJ-78436735 (also known as Ad26.COV2.S), is being developed primarily as a single vaccination, rather than in a ‘prime...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.